Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,516 GBX | +0.33% |
|
-0.75% | +4.43% |
02:45pm | That's not so bad, is it? | ![]() |
01:55pm | ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.43% | 78.92B | |
+56.89% | 823B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+14.15% | 239B | |
+15.05% | 220B | |
-0.08% | 219B | |
+7.94% | 167B | |
-2.57% | 159B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Citigroup Trims GSK PT, Maintains Buy Rating